Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Enlivex Therapeutics RDO Ltd.
Modality
monoclonal_antibody
Development Phase
Phase 1/2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
44High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05581719CT.gov A Phase 1/2a Study Evaluating Allocetra-OTS as Monotherapy or in Combination With Anti-PD-1 Therapy for the Treatment of Advanced Solid Tumor Malignancy | — | Terminated | — | — | — |
NCT03508570CT.gov Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
81High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Peritoneal Carcinomatosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Nivolumab (this asset) | Enlivex Therapeutics RDO Ltd. | P1/2 | CCC · 53 |
| Fluorouracilum | Ciusss de L'Est de l'Île de Montréal | P3 | BB |
| Cis-Diamminedichloroplatinum Ii | National Cancer Institute (NCI) | P3 | BB |
| Oxaliplatin | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P3 | BB |
| Muamycin | H. Lee Moffitt Cancer Center and Research Institute | P4 | BB |
| Irinotecan | Catharina Ziekenhuis Eindhoven | P3 | BB |
| Capecitabine | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | P2/3 | BB |
| Indocyanine Green | Jules Bordet Institute | P2 | B |
| Sodium Thiosulfate | National Cancer Institute (NCI) | P2 | B |
+33 more in the Peritoneal Carcinomatosis cohort
Other indications for Nivolumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Carcinoma | — | P4 | BBB · 72 |
| Metastatic Melanoma | — | P4 | BB · 70 |
| Non-Small Cell Lung Carcinoma | — | P4 | BB · 70 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- FluorouracilumCiusss de L'Est de l'Île de MontréalBB
- Cis-Diamminedichloroplatinum IiNational Cancer Institute (NCI)BB
- OxaliplatinDaping Hospital and the Research Institute of Surgery of the Third Military Medical UniversityBB
- MuamycinH. Lee Moffitt Cancer Center and Research InstituteBB
- IrinotecanCatharina Ziekenhuis EindhovenBB
Citation
Floatz Terminal. Nivolumab in Peritoneal Carcinomatosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/nivolumab-peritoneal-carcinomatosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →